Zirdafulven bladder cancer trial to test Lantern Pharma’s PTGR1 biomarker strategy
Lantern Pharma advances zirdafulven into a European Phase 1b/2 bladder cancer trial focused on PTGR1 and DNA repair biomarkers.
Pharma & Biotech
Pharma & Biotech
Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate
Lantern Pharma’s LP-300 showed an early EGFR L858R lung cancer signal. Read what the FDA meeting and trial redesign could change next.